Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CAO Andrew Schwendenman sold 2,148 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $21.60, for a total value of $46,396.80. Following the transaction, the chief accounting officer owned 97,277 shares in the company, valued at $2,101,183.20. This represents a 2.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Stock Performance
REPL traded up $0.12 during trading on Wednesday, hitting $19.81. 2,130,078 shares of the stock were exchanged, compared to its average volume of 3,489,130. The firm has a market capitalization of $1.88 billion, a P/E ratio of -7.10 and a beta of 0.93. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $23.54. The stock has a fifty day moving average price of $15.10 and a two-hundred day moving average price of $10.23. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.24. As a group, sell-side analysts predict that Replimune Group, Inc. will post -2.38 earnings per share for the current year.
Wall Street Analyst Weigh In
REPL has been the subject of several research reports. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, August 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of Replimune Group in a research report on Wednesday, November 4th. Leerink Partners lifted their price objective on shares of Replimune Group from $19.00 to $31.00 and gave the company an "outperform" rating in a research note on Thursday, October 29th. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Replimune Group in a report on Monday, October 5th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Replimune Group presently has an average rating of "Moderate Buy" and a consensus target price of $18.17.
Get Our Latest Research Report on REPL
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Replimune Group during the third quarter worth approximately $64,000. Allworth Financial LP acquired a new stake in shares of Replimune Group during the second quarter worth $62,000. Essential Partners LLC grew its position in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company's stock valued at $43,000 after buying an additional 5,624 shares during the last quarter. Legal & General Group Plc purchased a new position in Replimune Group in the 2nd quarter valued at $85,000. Finally, WINTON GROUP Ltd purchased a new position in Replimune Group in the 2nd quarter valued at $115,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.
About Replimune Group
(
Get Free Report)
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company's investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.